Latest Ueeshop News
Feb 2, 2021
publication date: Feb 2, 2021 Nantong Lianya Pharma, a division of Novast, completed a $62 million funding that was led by Highlight Capital, with participation from Shiyu Investment. The company has 40 US-approved difficult-to-make generic drugs including over 30 hormone products and nine oral controlled-release drugs. Lianya is applying for China approvals of the drugs. One year ago, it raised $140 million in private equity led by Legend Capital. Founded in 2005, Lianya focuses on drug delivery/extended release formulations of generics. More details.... Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .